MorphoSys welcomes Jean-Paul Kress as new CEO

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

14/10/2019
MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical...
16/09/2019
MorphoSys's Licensee Janssen Submits Biologics License Application to...
06/08/2019
MorphoSys AG Reports Second Quarter 2019 Financial Results
06/08/2019
MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND...
06/08/2019
MorphoSys Announces Intention to Submit Marketing Authorization...
25/07/2019
Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019
08/07/2019
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule...
03/07/2019
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program...
03/07/2019
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a...
24/06/2019
Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc:...

September 25, 2019
8th Annual Goldman Sachs and Berenberg German Corporate Conference
Munich, Germany

See conference